Abstract:The B-cell antigen receptor signaling pathway has been a primary focus in the targeted treatment of B-cell malignancies for the past decade. When aberrantly activated, this pathway initiates a cascade of phosphorylation mediated by several tyrosine kinases, with Bruton’s tyrosine kinase (BTK) being essential among them. Multiple generations of covalent and non-covalent BTK inhibitors have revolutionized therapeutic options for several B-cell lymphomas. However, the use of continuous BTK inhibition is limited by development of resistance resulting from acquired point mutations that allow persistent B-cell receptor signaling. Genomic sequencing of patient samples at disease progression has recently led to the discovery of novel resistance mutations in BTK that result in diminished or absent BTK kinase activity (termed kinase-deficient). However, the mechanisms underlying the potential advantage of kinase-deficient BTK mutations are incompletely understood and still under investigation. In this review, we provide a background of the pathway leading to the development of current therapies that target BTK and review the literature describing kinase-deficient BTK mutations. We propose that BTK inactivating mutations provide an advantage to neoplastic B-lymphocytes in patients with BTK inhibitor resistant B-cell malignancies and highlight potential mechanisms through which BTK kinase-deficient mutations could be acting, either due to differential protein conformation or by behaving as a scaffold for other signaling molecules. Due to the novelty of these mutations and their increasing rate of incidence over the last decade, it is imperative to continue studying BTK kinase deficient mutations across B-cell malignancies and to propose alternate therapies that could target them.

Navigating the changing landscape of BTK-targeted therapies for B cell lymphomas and chronic lymphocytic leukaemia

BTK inhibitors: past, present, and future

The Role of BTK Inhibition in the Treatment of Chronic Lymphocytic Leukemia: A Clinical View

New means and challenges in the targeting of BTK

Burgeoning Data on BTK Inactivating Mutations in Lymphomagenesis and Therapeutic Resistance

Advances in Targeted Therapy: Addressing Resistance to BTK Inhibition in B-Cell Lymphoid Malignancies

BTK Inhibitors in CLL: Second Generation Drugs and Beyond

Inhibiting Bruton’s Tyrosine Kinase in CLL and Other B-Cell Malignancies

Advances in the treatment of mantle cell lymphoma with BTK inhibitors

Resisting the Resistance: Navigating BTK Mutations in Chronic Lymphocytic Leukemia (CLL)

Progression of Bruton tyrosine kinase (BTK) inhibitor in B-cell lymphoma

Targeting the B cell receptor signaling pathway in chronic lymphocytic leukemia

The resistance mechanisms and treatment strategies of BTK inhibitors in B-cell lymphoma

Bruton’s Tyrosine Kinase (BTK) Inhibitors in Treating Cancer: a Patent Review (2010-2018)

BTK inhibitors: moving the needle on the treatment of chronic lymphocytic leukemia

Targeting Bruton's Tyrosine Kinase in CLL

Targeting Bruton'S Tyrosine Kinase For The Treatment Of B Cell Associated Malignancies And Autoimmune Diseases: Preclinical And Clinical Developments Of Small Molecule Inhibitors

Managing chronic lymphocytic leukemia in 2020: an update on recent clinical advances with a focus on BTK and BCL-2 inhibitors

Targeting Bruton’s Tyrosine Kinase in CLL

BTK Inhibitors in Chronic Lymphocytic Leukemia: Biological Activity and Immune Effects

The Evolving Role of Bruton's Tyrosine Kinase Inhibitors in B Cell Lymphomas